An interventional study of Intervention with telemedicine tool in Skin Cancer Prevention, Melanoma In Situ and Skin Lesions, sponsored by Institute of Health Information and Statistics of the Czech Republic. Recruiting at 5 sites in Czechia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Institute of Health Information and Statistics of the Czech Republic · Not applicable, Interventional, and Prevention
The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic.
The primary aim of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of skin tumors by using a telemedicine tools and setting up and testing new methods and implementation into the system of social health care.
The project is a national, prospective, multicenter, single-arm interventional pilot project for skin tumors screening involving 18 general practitioners and 6 dermatology centers in the Czech Republic.
The main objective of the project is the early detection of skin tumors by general practitioners, increasing the efficiency of healthcare, and methodically preparing, implementing, and evaluating the pilot project. The project aims to verify the suitability of the proposed early detection procedure for skin tumors, as well as to establish and test new methods and integrate them into the healthcare system.
As part of the project, the procedure will be tested on a sample of approximately 1,440 individuals, which may help validate the use of telemedicine tools in healthcare. A methodology for the use of telemedicine tools will be developed, along with a framework for collaboration between general practitioners and affiliated dermatologists. Systemic changes will be proposed to enhance the efficiency of the screening process.
The project is supported by the European Social Fund (Operational Programme Employment Plus) and the state budget of the Czech Republic. It is registered with the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0002008.
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
This study's planned enrollment of 1,440 is above the median of 40 across 2,649 interventional studies indexed under Melanoma.
Browse Melanoma studies →Institute of Health Information and Statistics of the Czech Republic is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pilot screening will be conducted in general practitioners' offices, where physicians will be trained to examine skin lesions using magnifying devices (dermatoscopes) and advanced telemedicine software, enabling faster diagnostics of suspicious findings. Patients with high-risk lesions will be referred to specialized dermatology centers.
Diagnostic Test: Intervention with telemedicine tool
The diagnostic management of enrolled patients will be guided by standardized procedures carried out in general practitioners' offices. Physicians will be trained to identify suspicious skin lesions, capture high-resolution images using dermatoscopes, and transfer the data into advanced telemedicine software. The platform, supported by AI-driven algorithms, enables precise risk stratification of lesions and facilitates remote consultation with collaborating dermatologists. Patients with high-risk lesions will be referred to specialized dermatology centers for further examination and intervention. In cases where excision of a lesion is performed, histopathological assessment will be conducted, and results will be systematically recorded within the dedicated telemedicine platform, ensuring secure and efficient information exchange between dermatologists and general practitioners.
Potential malignancies
Proportion of individuals with a potential presence of malignancy (detected through the telemedicine tool).
Time frame: From enrollment to the end of examination - baseline.
Confirmed malignancies
Proportion of individuals with confirmed potential malignancy by a dermatologist.
Time frame: From enrollment to the end of diagnosis at 3 months.
Confirmed malignancies by histology
Proportion of individuals in whom the diagnosis of malignancy was confirmed histologically.
Time frame: From enrollment to the end of diagnosis at 6 months.
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Aug 2026, 6 months.
Of 219 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 6 months is below that.
Counting every sponsor, half of 227 studies reached it within 38 months; a quarter within 20 and three quarters within 62.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Health Information and Statistics of the Czech Republic